Novartis showcases new data on MS drugs Mayzent and Kesimpta at ACTRIMS-ECTRIMS

12 September 2020

Swiss pharma giant Novartis (NOVN: VX) on Friday presented new data on two of its already marketed multiple sclerosis (MS) drugs, Kesimpta (ofatumumab), and blockbuster hopeful Mayzent (siponimod) at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

Novartis said that Mayzent analyses from the Phase IIIb EXCHANGE and EXPAND trials showed the drug to be a safe treatment option that has benefits in cognitive performance and reduces the risk of disability progression in patients with progressing MS.

“One of the biggest goals for people living with MS is to be able to live their lives independently for as long as possible," said Dr Norman Putzki, global head of development, neuroscience. “The data presented today reinforces that through its beneficial effects on cognitive performance and delaying disability progression, and as an appropriate option for patients to safely switch to/from other treatments, Mayzent offers hope for people looking to achieve this important goal,” he noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK